First approved new class of IBS-C therapy, Constella, now available in Europe

13 June 2013

Spain’s largest drugmaker Almirall (ALM: MC) and US partner Ironwood Pharmaceuticals, (Nasdaq: IRWD) today (June 13) announced the launch of Constella (linaclotide 290mcg capsules once daily), the first approved prescription therapy in a new class of treatments for adults suffering from moderate to severe IBS-C, in Europe. Constella is now available in Germany, the UK and Nordic countries and is expected to be launched in several other European countries in 2013.

Constella is the first and only product approved in the European Union for the treatment of IBS-C in adults and has been demonstrated in clinical trials to improve abdominal pain – one of the hallmark symptoms of IBS-C, as well as to improve constipation-related symptoms. IBS is a functional, chronic and relapsing gastrointestinal disorder affecting over 10% of the European population, and it is estimated that one-third of IBS patients suffer from IBS-C[ii]with different degrees of severity. Symptoms associated with IBS-C include abdominal pain and/or discomfort, bloating and constipation.

“The availability of linaclotide is excellent news for the one-third of adult IBS patients that have constipation. The symptoms associated with the condition can negatively impact the lives of patients. A targeted prescription treatment specifically for IBS-C is extremely welcome – for both appropriate patients and physicians alike who can now better manage this unpleasant, chronic condition,” said Eamonn Quigley, a professor and gastroenterologist at the University College Cork, Ireland, quoted by the companies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical